tradingkey.logo

Spruce Biosciences Announces New Corporate Strategy And Acquisition Of Tralesinidase Alfa

ReutersApr 15, 2025 11:09 AM

- Spruce Biosciences Inc SPRB.O:

  • SPRUCE BIOSCIENCES ANNOUNCES NEW CORPORATE STRATEGY AND ACQUISITION OF TRALESINIDASE ALFA FOR THE TREATMENT OF SANFILIPPO SYNDROME TYPE B (MPS IIIB)

  • SPRUCE BIOSCIENCES INC - BLA SUBMISSION TO FDA FOR TA-ERT ANTICIPATED IN 1H 2026

  • SPRUCE BIOSCIENCES INC: EXPECTS ITS CASH RUNWAY TO FUND ITS CURRENT OPERATING PLAN THROUGH END OF 2025

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI